A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
A Phase IV, Open Label, Randomized, Two-way Crossover, Single Dose Study to Determine
Relative Bioavailability of Alprazolam 0,75mg/ml (laboratórios Pfizer Ltda) in the Oral
Solution-drops Form, Versus Frontal® 0,25mg (laboratórios Pfizer Ltda), in the Tablets Form,
Under Fasted Conditions in Healthy Volunteers.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.